KNOWLEDGE *of* BIOSIMILARS

SURVEY OF 100+ U.S. RHEUMATOLOGISTS SHOWS FAMILIARITY BUT NEED FOR FURTHER EDUCATION



- Biologic medicines developed to be highly similar to an approved reference biologic, with no clinically meaningful differences in terms of safety, potency and purity
- Provide potential cost benefits to the healthcare system
- Increase availability of treatment options to those who rely on them for chronic or potentially life-threatening diseases

38% EXTREMELY
36% MODERATELY

Most physicians are extremely or moderately familiar with the FDA's definition of a biosimilar

96% EFFECTIVENESS
96% SAFETY
95% DURABILITY OF RESPONSE

Majority of respondents indicated that effectiveness, safety and durability of response were very or moderately important characteristics when comparing to originator biologic

74%

Indicated that an interchangeable designation was very or moderately important

71%

Aware that an approved biosimilar was not automatically deemed interchangeable by the FDA

66%

Extremely likely or likely to initiate biosimilar treatment if the approval included efficacy and safety studies in the same indication

5% EXTREMELY LIKELY
29% LIKELY

To initiate biosimilar treatment for a biologic treatment-naïve patient with a different rheumatologic condition than the one on which the biosimilar approval was based

131 physicians participated in a 20-question survey, administered by WebMD, between December 9 and 14, 2016. All participants were self-identified rheumatologists, practicing in the U.S. for more than 1 year.

Boehringer Ingelheim

MPR-US-100156